Synthesis, Structure−Activity Relationships, and Biological Evaluation of Fatty Alcohol Phosphates as Lysophosphatidic Acid Receptor Ligands, Activators of PPARγ, and Inhibitors of Autotaxin
- 22 June 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (15) , 4919-4930
- https://doi.org/10.1021/jm049609r
Abstract
We previously reported that fatty alcohol phosphates (FAP) represent a minimal pharmacophore required to interact with lysophosphatidic acid (LPA) receptors. To improve the activity of the first-generation saturated FAP series, a structure−activity relationship (SAR) study was carried out that includes modifications to the headgroup and alkyl side chain of the FAP pharmacophore. A series of unsaturated (C10−C18) FAP, headgroup-modified hydrolytically stable saturated (C10−C18) alkyl phosphonates, and saturated and unsaturated (C10−C18) thiophosphate analogues were synthesized and evaluated for activity in RH7777 cells transfected with individual LPA1-3 receptors, in PC-3 cells and in human platelets that endogenously express all three isoforms. In this series we identified several LPA1- and LPA3-selective antagonists with IC50 values in the nanomolar range. Oleoyl-thiophosphate (15g) was shown to be a pan-agonist, whereas tetradecyl-phosphonate (16c) was identified as a pan-antagonist. These compounds were also tested for the ability to activate the transcription factor PPARγ, an intracellular receptor for LPA, in CV1 cells transfected with the PPRE-Acox-Rluc reporter gene. All the FAP tested, along with the previously reported LPA GPCR antagonists dioctanoyl glycerol pyrophosphate (2), Ki16425 (6), and the agonist OMPT (3), were activators of PPARγ. The pan-agonist oleoyl-thiophosphate (15g) and pan-antagonist tetradecyl-phosphonate (16c) mimicked LPA in inhibiting autotaxin, a secreted lysophospholipase D that produces LPA in biological fluids.Keywords
This publication has 35 references indexed in Scilit:
- Enantioselective Responses to a Phosphorothioate Analogue of Lysophosphatidic Acid with LPA3Receptor-Selective Agonist ActivityJournal of Medicinal Chemistry, 2003
- Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid ReceptorsMolecular Pharmacology, 2003
- Plaque Rupture, Lysophosphatidic Acid, and ThrombosisCirculation, 2003
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003
- Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg FamilyJournal of Biological Chemistry, 2003
- Lysophosphatidic Acid-induced Mitogenesis Is Regulated by Lipid Phosphate Phosphatases and Is Edg-receptor IndependentJournal of Biological Chemistry, 2001
- Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA speciesFEBS Letters, 2000
- Bioactive Lysophospholipids and Their G Protein-Coupled ReceptorsExperimental Cell Research, 1999
- Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex.The Journal of cell biology, 1996
- Platelet Shape Change Induced by Thrombin Receptor Activation: RAPID STIMULATION OF TYROSINE PHOSPHORYLATION OF NOVEL PROTEIN SUBSTRATES THROUGH AN INTEGRIN- AND Ca 2+-INDEPENDENT MECHANISMPublished by Elsevier ,1995